Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes

American Journal of Physiology - Renal Physiology

Volumn 284, Issue 1 53-1, 2003, Pages

  DiPetrillo, Keith ^a   Coutermarsh, Bonita ^a   Gesek, Frank A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Albuminuria; Distal tubule; Hypertrophy; Sodium retention; TNFR:Fc

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; KIDNEY HYPERTROPHY; MALE; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SODIUM RETENTION; SODIUM TRANSPORT; STREPTOZOCIN DIABETES; URINARY EXCRETION;

EID: 0037213986     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00026.2002     Document Type: Article

References (50)

1. Allen TJ, Waldron MJ, Casley D, Jerums G, and Cooper ME. Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes. Diabetes 46: 19-24, 1997.
2. Argiles JM, Lopez-Soriano J, and Lopez-Soriano FJ. Cytokines and diabetes: The final step? Involvement of TNF-α in both type I and II diabetes mellitus. Horm Metab Res 26: 447-449, 1994.
3. Baumgartl HJ, Sigl G, Banholzer P, Haslbeck M, and Standl E. On the prognosis of IDDM patients with large kidneys. Nephrol Dial Transplant 13: 630-634, 1998.
4. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, and Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19: 1992-1997, 1999.
5. Choy EH and Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907-916, 2001.
6. Cottin V, Van Linden AA, and Riches DW. Phosphorylation of the tumor necrosis factor receptor CD120a (p55) recruits Bcl-2 and protects against apoptosis. J Biol Chem 276: 17252-17260, 2001.
7. Cottone S, Vadala A, Vella MC, Mule G, Contorno A, and Cerasola G. Comparison of tumour necrosis factor and endothelin-1 between essential and renal hypertensive patients. J Hum Hypertens 12: 351-354, 1998.
8. Diabetes Control and Complications Trial Research Group. Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
9. Foss MC, Foss NT, Paccola GM, and Silva CL. Serum levels of tumor necrosis factor in insulin-dependent diabetic patients. Braz J Med Biol Res 25: 239-242, 1992.
10. Friedman PA and Gesek FA. Cellular calcium transport in renal epithelia: Measurement, mechanisms, and regulation. Physiol Rev 75: 429-471, 1995.
11. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, and Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421-426, 2001.
12. 2-adrenoceptor control of sodium transport reverses in developing hypertension. Hypertension 33: 524-529, 1999.
13. Gesek FA and Friedman PA. On the mechanism of parathyroid hormone stimulation of calcium uptake by mouse distal convoluted tubule cells. J Clin Invest 90: 749-758, 1992.
14. Gesek FA and Friedman PA. Sodium entry mechanisms in distal convoluted tubule cells. Am J Physiol Renal Fluid Electrolyte Physiol 268: F89-F98, 1995.
15. + exchanger. Am J Physiol Renal Fluid Electrolyte Physiol 258: F514-F521, 1990.
16. Gesek FA, Wolff DW, and Strandhoy JW. Improved separation method for rat proximal and distal renal tubules. Am J Physiol Renal Fluid Electrolyte Physiol 253: F358-F365, 1987.
17. Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR, Garcia-Bulnes G, Salas-Ramirez M, and Amato D. Pentoxifylline reduces proteinuria in insulin-dependent and non-insulin-dependent diabetic patients. Clin Nephrol 43: 116-121, 1995.
18. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K, and Kondo M. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40: 1007-1012, 1991.
19. Jevnikar AM, Brennan DC, Singer GG, Heng JE, Maslinski W, Wuthrich RP, Glimcher LH, and Kelley VE. Stimulated kidney tubular epithelial cells express membrane-associated and secreted TNF-α. Kidney Int 40: 203-211, 1991.
20. Jevnikar AM, Wuthrich RP, Brennan DC, Maslinski W, Glimcher LH, and Rubin-Kelley VE. TNF-α is expressed on the surface of kidney proximal tubular cells. Transplant Proc 23: 231-232, 1991.
21. Kleinman KS and Fine LG. Prognostic implications of renal hypertrophy in diabetes mellitus. Diabetes Metab Rev 4: 179-189, 1988.
22. Lechleitner M, Koch T, Herold M, and Hoppichler F. Relationship of tumor necrosis factor-α plasma levels to metabolic control in type 1 diabetes. Diabetes Care 22: 1749, 1999.
23. Mogensen CE, Christensen CK, and Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32 Suppl 2: 64-78, 1983.
24. Molitch ME, DeFronzo RA, Franz MA, Keane WF, Mogensen CE, Parving H, and Steffes MW. Diabetic nephropathy. Diabetes Care 23: S69-S73, 2000.
25. Muc-Wierzgon M, Baranowski M, and Madej K. Monitoring of changes in levels of endogenous TNF-α in patients with uncontrolled insulin-dependent diabetes mellitus. Pol Arch Med Wewn 97: 426-432, 1997.
26. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, and Koide H. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42: 450-456, 1993.
27. Navarro JF and Mora C. Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy, Diabetes Care 22: 1006-1008, 1999.
28. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macia M, Mendez ML, and Garcia J. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am J Kidney Dis 33: 458-463, 1999.
29. O'Hare JA, Ferriss JB, Brady D, Twomey B, and O'Sullivan DJ. Exchangeable sodium and renin in hypertensive diabetic patients with and without nephropathy. Hypertension 7: 1143-1148, 1985.
30. Peach RJ, Day WA, Ellingsen PJ, and McGiven AR. Ultrastructural localization of Tamm-Horsfall protein in human kidney using immunogold electron microscopy. Histochem J 20: 156-164, 1988.
31. 1-microglobulin and Tamm-Horsfall protein. Clin Investig 71: 972-977, 1993.
32. Pizzonia JH, Gesek FA, Kennedy SM, Coutermarsh BA, Bacskai BJ, and Friedman PA. Immunomagnetic separation, primary culture, and characterization of cortical thick ascending limb plus distal convoluted tubule cells from mouse kidney. In Vitro Cell Dev Biol 27A: 409-416, 1991.
33. Rachmani R, Levi Z, Lidar M, Slavachevski I, Half-Onn E, and Ravid M. Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: Lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract 49: 187-194, 2000.
34. Rasch R and Dorup J. Quantitative morphology of the rat kidney during diabetes mellitus and insulin treatment. Diabetologia 40: 802-809, 1997.
35. Rasch R, Torffvit O, Bachmann S, Jensen PK, and Jacobsen NO. Tamm-Horsfall glycoprotein in streptozotocin diabetic rats: A study of kidney in situ hybridization, immunohistochemistry, and urinary excretion. Diabetologia 38: 525-535, 1995.
36. Reeves WB and Andreoli TE. Transforming growth factor-β contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 97: 7667-7669, 2000.
37. Reichard P, Nilsson BY, and Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329: 304-309, 1993.
38. Rothe J, Gehr G, Loetscher H, and Lesslauer W. Tumor necrosis factor receptors - Structure and function. Immunol Res 11: 81-90, 1992.
39. Sato A, Tarnow L, and Parving HH. Prevalence of left ventricular hypertrophy in type I diabetic patients with diabetic nephropathy. Diabetologia 42: 76-80, 1999.
40. Sikri KL, Alexander DP, and Foster CL. Localization of Tamm-Horsfall glycoprotein in the normal rat kidney and the effect of adrenalectomy on its localization in the hamster and rat kidney. J Anat 135: 29-45, 1982.
41. Strojek K, Grzeszczak W, Lacka B, Gorska J, Keller CK, and Ritz E. Increased prevalence of salt sensitivity of blood pressure in IDDM with and without microalbuminuria. Diabetologia 38: 1443-1448, 1995.
42. Sugimoto H, Shikata K, Wada J, Horiuchi S, and Makino H. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: Aminoguanidine ameliorates the overexpression of tumour necrosis factor-a and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 42: 878-886, 1999.
43. Thomson SC, Deng A, Bao D, Satriano J, Blantz RC, and Vallon V. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest 107: 217-224, 2001.
44. Weder AB. Sodium metabolism, hypertension, and diabetes. Am J Med Sci 307 Suppl 1: S53-S59, 1994.
45. Weidmann P, Beretta-Piccoli C, and Trost BN. Pressor factors and responsiveness in hypertension accompanying diabetes mellitus. Hypertension 7: 1133-1142, 1985.
46. Weidmann P, Boehlen LM, and de Courten M. Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J 125: 1498-1513, 1993.
47. Yong LC and Bleasel AF. Pathological changes in streptozotocin-induced diabetes mellitus in the rat. Exp Pathol (Jena) 30: 97-107, 1986.
48. Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, and Johnston CI. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 98: 2621-2628, 1998.
49. Zhou MS, Nishida Y, Yoneyama H, Chen QH, and Kosaka H. Potassium supplementation increases sodium excretion and nitric oxide production in hypertensive Dahl rats. Clin Exp Hypertens 21: 1397-1411, 1999.
50. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, and Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020, 2000.